noscript

News and Announcements

Sun Biomedical Tapping into US$11B Kidney Disease Sector

  • Published June 30, 2015 3:37PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

June 30th 2015 by Proactive Investors

Sun Biomedical (ASX:SBN) is proceeding with the acquisition of platform drug discovery and clinical stage biotechnology company Dimerix Bioscience after satisfying all conditions precedent.

The transaction is now unconditional and should be completed by the close of business on 3rd July 2015.

Dimerix is currently recruiting in to Phase 2 clinical study for its lead therapeutic product DMX200 that is targeted at patients with chronic kidney disease (CKD).

CKD affects over 26 million people in the U.S. alone. The market in exceeds $11 billion in sales per annum and continues to grow.

Dimerix’s initial strategy is to pursue an orphan indication, Nephrotic Syndrome, and subsequently partner the development of programs in larger disease indications.

It is engaged in research collaborations with top pharmaceutical companies using its proprietary GPCR (G protein coupled receptors) drug discovery platform.

To read the full story, please click here.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now